Bruce N. Jacobs, Chief Financial Officer at Kymera Therapeutics, Inc. (KYMR), sold 79,220 shares at $50.00 ($4.0M) on 2025-09-17, disclosed to the SEC on 2025-09-17.
Scheduled sale ($4.0M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| KYMR | SELL | 2025-03-03 | $389K | — | Filing → |
| KYMR | SELL | 2024-03-04 | $318K | — | Filing → |
| KYMR | SELL | 2023-03-03 | $42K | — | Filing → |